You are here: Home » Government Press Release » News
Business Standard

CCRAS developed and commercialized Ayurvedic Drugs

CCRAS developed and commercialized Ayurvedic Drugs

The Central Council for Research in Ayurvedic Sciences (CCRAS), an autonomous body under the Ministry of AYUSH is actively involved in scientific process of drug development adopting prevalent guidelines such as Good Clinical Practices Guidelines for ASU drugs (GCP-ASU), Ministry of AYUSH and National ethical guidelines for Bio-Medical Research (ICMR), WHO guidelines for traditional medicines etc. as per requirement and as feasible through its peripheral institutes. Council through its drug development program is undertaking development of new formulations/drugs taking leads from Ayurvedic literature through a systematic process of drug development. viz standardization, preclinical safety & clinical study as per requirement.

CCRAS has developed and commercialized the following two drugs:

  1. AYUSH 82 An Anti Diabetic Ayurvedic Formulation
  2. AYUSH SG An Anti-Rheumatoid Arthritis preparation.

CCRAS has also undertaken the development of the following coded formulations which are at different phases of drug development:-

  1. AYUSH Manas for Mental retardation/cognitive deficit
  2. AYUSH QOL 2C for improving Quality of Life of Cancer patients
  3. AYUSH Rasayan A & B in geriatric health
  4. AYUSH C1 Oil for wound healing
  5. AYUSH PJ-7 for Dengue fever
  6. AYUSH M-3 for Migraine
  7. AYUSH SL for Filariasis
  8. AYUSH A for Bronchial Asthma
  9. AYUSH D for Type II Diabetes Mellitus
  10. Carctol S for Cancer
  11. AYUSH K1 for Chronic Kidney Diseases

This information was given by the Minister of State (Independent Charge) for AYUSH, Shri Shripad Yesso Naik in written reply to a question in Rajya Sabha today.


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 06 2018. 00:20 IST